207 related articles for article (PubMed ID: 38104151)
1. Targeting ST8SIA6-AS1 counteracts KRAS
Wang Y; Yao M; Li C; Yang K; Qin X; Xu L; Shi S; Yu C; Meng X; Xie C
Exp Hematol Oncol; 2023 Dec; 12(1):105. PubMed ID: 38104151
[TBL] [Abstract][Full Text] [Related]
2. Targeting PI3Kα overcomes resistance to KRas
Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway.
Qiao Y; Wang B; Yan Y; Niu L
Environ Toxicol; 2022 Oct; 37(10):2398-2411. PubMed ID: 35730485
[TBL] [Abstract][Full Text] [Related]
4. The Role of APAL/ST8SIA6-AS1 lncRNA in PLK1 Activation and Mitotic Catastrophe of Tumor Cells.
Luo ML; Li J; Shen L; Chu J; Guo Q; Liang G; Wu W; Chen J; Chen R; Song E
J Natl Cancer Inst; 2020 Apr; 112(4):356-368. PubMed ID: 31286138
[TBL] [Abstract][Full Text] [Related]
5. LncRNA ST8SIA6-AS1 Promotes Cholangiocarcinoma Progression by Suppressing the miR-145-5p/MAL2 Axis.
He J; Yan H; Wei S; Chen G
Onco Targets Ther; 2021; 14():3209-3223. PubMed ID: 34040387
[TBL] [Abstract][Full Text] [Related]
6. LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma cell proliferation and resistance to apoptosis by targeting miR-4656/HDAC11 axis.
Fei Q; Song F; Jiang X; Hong H; Xu X; Jin Z; Zhu X; Dai B; Yang J; Sui C; Xu M
Cancer Cell Int; 2020; 20():232. PubMed ID: 32536820
[TBL] [Abstract][Full Text] [Related]
7. LncRNA ST8SIA6-AS1 promotes proliferation, migration and invasion in breast cancer through the p38 MAPK signalling pathway.
Fang K; Hu C; Zhang X; Hou Y; Gao D; Guo Z; Li L
Carcinogenesis; 2020 Sep; 41(9):1273-1281. PubMed ID: 31784750
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
9. LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma progression by regulating MAGEA3 and DCAF4L2 expression.
Zhang X; Xu S; Hu C; Fang K; Zhou J; Guo Z; Zhu G; Li L
Biochem Biophys Res Commun; 2020 Dec; 533(4):1039-1047. PubMed ID: 33012505
[TBL] [Abstract][Full Text] [Related]
10. LncRNA ST8SIA6-AS1 promotes colorectal cancer cell proliferation, migration and invasion by regulating the miR-5195/PCBP2 axis.
Huang CM; Cao GY; Yang CX; Chen Y; Liu GD; Xu BW; Zhang X
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4203-4211. PubMed ID: 32373956
[TBL] [Abstract][Full Text] [Related]
11. ST8SIA6-AS1 contributes to hepatocellular carcinoma progression by targeting miR-142-3p/HMGA1 axis.
Feng T; Yao Y; Luo L; Zou H; Xiang G; Wei L; Yang Q; Shi Y; Huang X; Lai C
Sci Rep; 2023 Jan; 13(1):650. PubMed ID: 36635290
[TBL] [Abstract][Full Text] [Related]
12. SHP2 Contributes to Resistance of KRAS p.G12C-Driven Lung Cancer Cells to MRTX849 by Regulating β-catenin/c-MYC Axis.
Li W; Wu Y; Dai L; Wang W; Zhao L
Ann Clin Lab Sci; 2023 Jul; 53(4):630-640. PubMed ID: 37625842
[TBL] [Abstract][Full Text] [Related]
13. Resistance to KRAS
Blaquier JB; Cardona AF; Recondo G
Front Oncol; 2021; 11():787585. PubMed ID: 35004309
[No Abstract] [Full Text] [Related]
14. ST8SIA6-AS1 promotes the development of hepatocellular carcinoma cells through miR-338-3p/NONO Axis.
Kuai J; Zheng L; Yi X; Liu Z; Qiu B; Lu Z; Jiang Y
Dig Liver Dis; 2021 Sep; 53(9):1192-1200. PubMed ID: 33722502
[TBL] [Abstract][Full Text] [Related]
15. A Breakthrough Brought about by Targeting KRAS
Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550
[TBL] [Abstract][Full Text] [Related]
16. ST8SIA6-AS1 promotes hepatocellular carcinoma by absorbing miR-5195-3p to regulate HOXB6.
Li Y; Jiang A
Cancer Biol Ther; 2020 Jul; 21(7):647-655. PubMed ID: 32420798
[TBL] [Abstract][Full Text] [Related]
17. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
18. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
19. LncRNA ST8SIA6-AS1 facilitates hepatocellular carcinoma progression by governing miR-651-5p/TM4SF4 axis.
Mou Y; Ding X
Anticancer Drugs; 2022 Sep; 33(8):741-751. PubMed ID: 35946523
[TBL] [Abstract][Full Text] [Related]
20. 143D, a novel selective KRAS
Xu LS; Zheng SX; Mei LH; Yang KX; Wang YF; Zhou Q; Kong XT; Zheng MY; Jiang HL; Xie CY
Acta Pharmacol Sin; 2023 Jul; 44(7):1475-1486. PubMed ID: 36725884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
